{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:23:02Z","timestamp":1790508182676,"version":"4.1.0"},"reference-count":60,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Formaci\u00f3n de Profesorado Universitario","award":["FPU19\/04933"],"award-info":[{"award-number":["FPU19\/04933"]}]},{"DOI":"10.13039\/100008052","name":"Alfonso Martin Escudero Foundation","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008052","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Regional Program of Research and Technological Innovation for Young Doctors UCM-CAM","award":["PR27\/21-031"],"award-info":[{"award-number":["PR27\/21-031"]}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-123056OA-I00"],"award-info":[{"award-number":["PID2021-123056OA-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008782","name":"Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100008782","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of Science, Innovation and Universities of Spain","award":["FPU19\/04933"],"award-info":[{"award-number":["FPU19\/04933"]}]},{"DOI":"10.13039\/100018857","name":"International Myeloma Society","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100018857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CRIS Contra el C\u00e1ncer Foundation","award":["2021\/0088"],"award-info":[{"award-number":["2021\/0088"]}]},{"name":"CRIS Contra el C\u00e1ncer Foundation","award":["2024\/0031"],"award-info":[{"award-number":["2024\/0031"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The gut microbiota plays a critical role in regulating immune homeostasis and modulating responses to cancer immunotherapies. However, the impact of antibiotic-induced dysbiosis in patients with multiple myeloma (MM) treated with bispecific antibodies (BsAbs) remains unexplored. This multicenter, international study investigated whether antibiotic exposure prior to BsAb initiation alters the gut microbiome and affects clinical outcomes in patients with relapsed or refractory MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 237 adult patients with MM treated with CD3-engaging BsAbs across six academic institutions. Antibiotic exposure was defined as the administration of any broad-spectrum, non-prophylactic antibiotic within 30 days before BsAb initiation. Clinical outcomes included overall survival (OS), progression-free survival (PFS), and cumulative incidence of relapse, evaluated using Kaplan-Meier estimates, log-rank tests, and multivariable Cox and competing-risk regression models. Additionally, in a subset of 24 patients, peripheral blood samples were collected prior to BsAb infusion for immunophenotyping, cytokine profiling, and serum short-chain fatty acid (SCFA) quantification, while stool samples for 16S ribosomal RNA (rRNA) sequencing were collected in a subset of 19 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Broad-spectrum antibiotic exposure prior to BsAb therapy was associated with significantly inferior 1-year OS (60% (95% CI 44% to 81%)\u2009vs 77% (95% CI 71% to 83%), p=0.004) and PFS (26% (95% CI 14% to 47%)\u2009vs 53% (95% CI 46% to 61%), p&lt;0.001), and higher relapse incidence (68% (95% CI 48% to 82%)\u2009vs 43% (95% CI 36% to 50%), p=0.004). In multivariable analyses, antibiotic exposure remained independently associated with poorer OS, PFS, and higher relapse risk. These associations were also observed within the subgroup of patients treated with CD3\/B-cell maturation antibody-targeted BsAbs (n=155). Immunoprofiling revealed lower CD4\n                      <jats:sup>+<\/jats:sup>\n                      T-cell counts (p=0.017) and reduced circulating cytokine levels among antibiotic-exposed patients. 16S rRNA sequencing demonstrated a marked depletion of SCFA-producing genera, including\n                      <jats:italic>Roseburia<\/jats:italic>\n                      and\n                      <jats:italic>Eubacterium<\/jats:italic>\n                      , accompanied by lower serum SCFA concentrations. Moreover, microbiota composition before BsAb treatment correlated with therapy response and treatment-related toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antibiotic-induced dysbiosis prior to BsAb therapy is associated with impaired immune reconstitution and inferior clinical outcomes in MM. These findings underscore the importance of antibiotic stewardship and suggest that microbiota-preserving strategies could enhance the efficacy of BsAb therapy in MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014224","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:35:40Z","timestamp":1772807740000},"page":"e014224","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6553-0171","authenticated-orcid":false,"given":"Magdalena","family":"Corona","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Garc\u00eda-Vicente","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7372-5219","authenticated-orcid":false,"given":"Adolfo Jes\u00fas","family":"Saez-Marin","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ancos-Pintado","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, Madrid, Spain"},{"name":"Department of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Rodr\u00edguez-Garcia","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Arroyo","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Blanco","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Hematology Department, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"additional","affiliation":[{"name":"Hematology Department, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wolf","sequence":"additional","affiliation":[{"name":"Hematology Department, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rey-Bua","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Clinico Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Clinico Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Riedhammer","sequence":"additional","affiliation":[{"name":"Hematology Department, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E","family":"Tamariz-Amador","sequence":"additional","affiliation":[{"name":"Hematology Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Valencia","sequence":"additional","affiliation":[{"name":"Hematology Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[{"name":"Hematology Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Hematology Department, Cl\u00ednica Universidad de Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys","family":"Ibarra","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Germans Trias i Pujol, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Cedena","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Alonso","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Calbacho","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Mar\u00eda","family":"Sanchez-Pina","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Linares","sequence":"additional","affiliation":[{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, Madrid, Spain"},{"name":"Department of Biochemistry and Molecular Biology, Pharmacy School, Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"},{"name":"Department of Translational Hematology, Instituto de Investigaci\u00f3n Hospital 12 de Octubre (imas12), Hematological Malignancies Clinical Research Unit H12O-CNIO, Madrid, Spain"},{"name":"Department of Medicine, Medicine School, Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"key":"2026030606351846000_14.3.e014224.1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738915","article-title":"Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia","volume":"12","author":"Allegra","year":"2021","journal-title":"Front Immunol"},{"key":"2026030606351846000_14.3.e014224.2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.117176"},{"key":"2026030606351846000_14.3.e014224.3","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/psp4.12345","article-title":"Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant","volume":"7","author":"Cho","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026030606351846000_14.3.e014224.4","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0371-5","article-title":"Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy","volume":"6","author":"Giles","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026030606351846000_14.3.e014224.5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"key":"2026030606351846000_14.3.e014224.6","doi-asserted-by":"publisher","DOI":"10.1086\/605664"},{"key":"2026030606351846000_14.3.e014224.7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714"},{"key":"2026030606351846000_14.3.e014224.8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.60"},{"key":"2026030606351846000_14.3.e014224.9","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Thiruvengadam","year":"2022","journal-title":"Blood Adv"},{"key":"2026030606351846000_14.3.e014224.10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ejh.13374","article-title":"Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis","volume":"104","author":"Mohyuddin","year":"2020","journal-title":"Eur J Haematol"},{"key":"2026030606351846000_14.3.e014224.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(95)00043-7"},{"key":"2026030606351846000_14.3.e014224.12","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-132134","article-title":"Severe Infections and Antibiotic Use Negatively Impact Progression Free and Overall Survival of Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation","volume":"134","author":"McKenna","year":"2019","journal-title":"Blood"},{"key":"2026030606351846000_14.3.e014224.13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1258506","article-title":"The influence of gut-decontamination prophylactic antibiotics on acute graft-versus-host disease and survival following allogeneic hematopoietic stem cell transplantation","volume":"6","author":"Routy","year":"2017","journal-title":"Oncoimmunology"},{"key":"2026030606351846000_14.3.e014224.14","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312297"},{"key":"2026030606351846000_14.3.e014224.15","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.42"},{"key":"2026030606351846000_14.3.e014224.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-832519"},{"key":"2026030606351846000_14.3.e014224.17","doi-asserted-by":"crossref","first-page":"1058272","DOI":"10.3389\/fimmu.2022.1058272","article-title":"Gut microbiome in multiple myeloma: Mechanisms of progression and clinical applications","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"2026030606351846000_14.3.e014224.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat Commun"},{"key":"2026030606351846000_14.3.e014224.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.041"},{"key":"2026030606351846000_14.3.e014224.20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1078-0432.CCR-23-0195","article-title":"Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma","volume":"30","author":"Rodr\u00edguez-Garc\u00eda","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026030606351846000_14.3.e014224.21","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-023-00442-x","article-title":"Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target","volume":"12","author":"Zhang","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"2026030606351846000_14.3.e014224.22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac4255"},{"key":"2026030606351846000_14.3.e014224.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900623"},{"key":"2026030606351846000_14.3.e014224.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-691394"},{"key":"2026030606351846000_14.3.e014224.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01702-9"},{"key":"2026030606351846000_14.3.e014224.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02234-6"},{"key":"2026030606351846000_14.3.e014224.27","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2203478"},{"key":"2026030606351846000_14.3.e014224.28","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204591"},{"key":"2026030606351846000_14.3.e014224.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"2026030606351846000_14.3.e014224.30","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"key":"2026030606351846000_14.3.e014224.31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"2026030606351846000_14.3.e014224.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2026030606351846000_14.3.e014224.33","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10071341","article-title":"In Silico Genomic and Metabolic Atlas of Limosilactobacillus reuteri DSM 20016: An Insight into Human Health","volume":"10","author":"Smythe","year":"2022","journal-title":"Microorganisms"},{"key":"2026030606351846000_14.3.e014224.34","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.757718","article-title":"Roseburia intestinalis: A Beneficial Gut Organism From the Discoveries in Genus and Species","volume":"11","author":"Nie","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"2026030606351846000_14.3.e014224.35","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2020.1802866","article-title":"Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health","volume":"12","author":"Mukherjee","year":"2020","journal-title":"Gut Microbes"},{"key":"2026030606351846000_14.3.e014224.36","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2020.12190","article-title":"A gut butyrate-producing bacterium Butyricicoccus pullicaecorum regulates short-chain fatty acid transporter and receptor to reduce the progression of 1,2-dimethylhydrazine-associated colorectal cancer","volume":"20","author":"Chang","year":"2020","journal-title":"Oncol Lett"},{"key":"2026030606351846000_14.3.e014224.37","doi-asserted-by":"crossref","DOI":"10.3390\/nu15092211","article-title":"Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota","volume":"15","author":"Fusco","year":"2023","journal-title":"Nutrients"},{"key":"2026030606351846000_14.3.e014224.38","doi-asserted-by":"crossref","DOI":"10.1038\/s41522-020-0119-0","article-title":"Short-term supplementation of celecoxib-shifted butyrate production on a simulated model of the gut microbial ecosystem and ameliorated in vitro inflammation","volume":"6","author":"Hernandez-Sanabria","year":"2020","journal-title":"NPJ Biofilms Microbiomes"},{"key":"2026030606351846000_14.3.e014224.39","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2018.1534512"},{"key":"2026030606351846000_14.3.e014224.40","doi-asserted-by":"publisher","DOI":"10.1099\/ijs.0.017533-0"},{"key":"2026030606351846000_14.3.e014224.41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103293","article-title":"Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?","volume":"66","author":"Deleu","year":"2021","journal-title":"EBioMedicine"},{"key":"2026030606351846000_14.3.e014224.42","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1038\/s41467-022-32960-3","article-title":"CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies","volume":"13","author":"Hu","year":"2022","journal-title":"Nat Commun"},{"key":"2026030606351846000_14.3.e014224.43","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.975436","article-title":"Pleiotropic effects of antibiotics on T cell metabolism and T cell-mediated immunity","volume":"13","author":"Franz","year":"2022","journal-title":"Front Microbiol"},{"key":"2026030606351846000_14.3.e014224.44","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00874-2"},{"key":"2026030606351846000_14.3.e014224.45","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00104-12"},{"key":"2026030606351846000_14.3.e014224.46","doi-asserted-by":"crossref","first-page":"357","DOI":"10.18433\/J3Z32F","article-title":"Effects of Macrolide Antibiotics on Th1 Cell and Th2 Cell Development Mediated by Langerhans Cells","volume":"19","author":"Matsui","year":"2016","journal-title":"J Pharm Pharm Sci"},{"key":"2026030606351846000_14.3.e014224.47","doi-asserted-by":"crossref","first-page":"1367053","DOI":"10.3389\/fimmu.2024.1367053","article-title":"Intestinal microflora promotes Th2-mediated immunity through NLRP3 in damp and heat environments","volume":"15","author":"Luo","year":"2024","journal-title":"Front Immunol"},{"key":"2026030606351846000_14.3.e014224.48","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2016.43","article-title":"Antibiotic-Induced Gut Microbiota Disruption Decreases TNF-alpha Release by Mononuclear Cells in Healthy Adults","volume":"7","author":"Lankelma","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"2026030606351846000_14.3.e014224.49","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.2.4.354"},{"key":"2026030606351846000_14.3.e014224.50","doi-asserted-by":"crossref","first-page":"106129","DOI":"10.1016\/j.phrs.2022.106129","article-title":"Gut microbiota and its role in stress-induced hyperalgesia: Gender-specific responses linked to different changes in serum metabolites","volume":"177","author":"Xu","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026030606351846000_14.3.e014224.51","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2249143","article-title":"Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell","volume":"15","author":"Zhu","year":"2023","journal-title":"Gut Microbes"},{"key":"2026030606351846000_14.3.e014224.52","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01014-8"},{"key":"2026030606351846000_14.3.e014224.53","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood.2023020026","article-title":"Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children","volume":"142","author":"Masetti","year":"2023","journal-title":"Blood"},{"key":"2026030606351846000_14.3.e014224.54","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","article-title":"The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC","volume":"14","author":"Jin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026030606351846000_14.3.e014224.55","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019032276"},{"key":"2026030606351846000_14.3.e014224.56","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1158\/1078-0432.CCR-22-0723","article-title":"Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets","volume":"28","author":"Shah","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026030606351846000_14.3.e014224.57","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/cid\/ciae487","article-title":"The Heterogeneous Syndrome of Noninfectious Causes of Persistent Fever in Neutropenic Patients With Hematologic Malignancy: Another Opportunity for Stewardship?","volume":"79","author":"Aslan","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026030606351846000_14.3.e014224.58","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae398","article-title":"Chimeric Antigen Receptor T-Cell Postinfusion Fever: Infection Profile, Clinical Parameters, and Biomarkers Trends to Assist Antibiotic Stewardship","volume":"11","author":"Peyrony","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026030606351846000_14.3.e014224.59","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(17)30211-9","article-title":"Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial","volume":"4","author":"Aguilar-Guisado","year":"2017","journal-title":"Lancet Haematol"},{"key":"2026030606351846000_14.3.e014224.60","unstructured":"Corona M , Garc\u00eda-Vicente R , Saez-Mar\u00edn AJ . n.d. Data from: Impact of Antibiotic-Associated Dysbiosis on Outcomes of Bispecific Antibody Treatment in Multiple Myeloma. NCBI BioProject."}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:35:47Z","timestamp":1772807747000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":60,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,6]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/jitc-2025-014224"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014224","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}